Replies to post #7804 on Repros Therapeutics, Inc. (RPRX)

[DewDiligence]

Repros expects to commence the Phase III studies early in 2011 and, depending on the rate of recruitment, to have reportable data from one of the studies near the end of that year.

An utterly and completely unrealistic timeline.

[mlkrborn]

Repros shares skyrocket on drug news
Houston Business Journal - by Greg Barr
Date: Thursday, December 23, 2010, 2:28pm CST - Last Modified: Thursday, December 23, 2010, 4:57pm CST
Related:
Health Care
Related News

Repros shares up on successful Proellex test
Repros shares fall on FDA recommendation
IDEV Technologies gets FDA approval for stent systems
Doing biotech business in Japan 101
Repros regains stock listing compliance

Shares of Repros Therapeutics Inc. nearly doubled in value Thursday in heavy volume after the company reported positive developments for its experimental testosterone deficiency drug, Androxal.

Repros (NASDAQ: RPRX) said in a statement that it had sent additional data to the U.S. Food and Drug Administration showing that a single assessment of testosterone levels collected in the morning correlates to maximum and average levels of testosterone during a 24-hour period in subjects taking Androxal.


Read more: Repros shares skyrocket on drug news | Houston Business Journal